Ir para o conteúdo principal

Infelizmente, não oferecemos suporte total ao seu navegador. Se for possível, atualize para uma versão mais recente ou use o Mozilla Firefox, o Microsoft Edge, o Google Chrome ou o Safari 14 ou mais recente. Se não conseguir e precisar de suporte, envie seu feedback.

Gostaríamos de receber seu feedback sobre essa nova experiência.Diga-nos sua opiniãoabre em uma nova guia/janela

Elsevier
Publique conosco
Press release

Posttraumatic brain activity predicts resilience to PTSD

Philadelphia | 21 de setembro de 2023

Imaging study in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging provides hints to PTSD pathology

After a traumatic experience, most people recover without incident, but some people – between 2% and 10%– develop posttraumatic stress disorder (PTSD), a mental health condition that can cause debilitating symptoms of anxiety due to emotional dysregulation. PTSD symptoms are present in up to 40% of trauma survivors in the acute aftermath of trauma, but full-blown PTSD develops in only a small subset of cases. Early identification of those at risk is critical for both early treatment and possible prevention.

A new studyopens in new tab/window led by Israel Liberzon, MD, at Texas A&M University, aimed to do just that. The study appears in Biological Psychiatry: Cognitive Neuroscience and Neuroimagingopens in new tab/window, published by Elsevier.

Researchers have long understood that PTSD involves altered brain processing in areas associated with emotion processing and modulation, including the amygdala, insula, and prefrontal cortex. But, it has remained unclear when the PTSD-associated differences arise. In this work, the researchers collected brain scans from 104 survivors of trauma – usually a car accident – at 1, 6, and 14 months after the accident. By looking at brain activity so soon after the trauma, the researchers hoped to identify predictors of who would be more at risk or resilient to developing chronic PTSD.

Dr. Liberzon said of the findings, “In this largest-to-date, prospective study of early post-trauma survivors, greater activation in right inferior frontal gyrus, a region linked to cognitive control and emotional reappraisal, predicts better recovery from early PTSD symptoms. These findings highlight the key roles of cortical/cognitive regions in regulation of fear and in PTSD development.”

Importantly, the researchers saw changes in the patients’ brain activity change over time, reflecting an ongoing, perhaps pathological process.

Cameron Carter, MD, Editor of Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, said of the study, “These findings highlight the key role that the prefrontal cortex may play in conferring resilience to the harmful effects of trauma, through its function representing contextual information and regulating emotional responses.”

Dr. Liberzon added, “Understanding brain circuits linked to the progression of PTSD from an acute to a chronic condition is critical for understanding its pathophysiology, and eventually for the development of mechanism-informed treatment. The results might also help clinicians to start identifying and treating early trauma survivors at greater risk of developing chronic PTSD a year after the traumatic event.”

---

Notes for editors

The article is "Greater Early Post-Trauma Activation in Right Inferior Frontal Gyrus Predicts Recovery from Posttraumatic Stress Disorder Symptoms," by Jony Sheynin, Yana Lokshina, Samira Ahrari, Tetiana Nickelsen, Elizabeth R. Duval, Ziv Ben-Zion, Arieh Y. Shalev, Talma Hendler, and Israel Liberzon (https://doi.org/10.1016/j.bpsc.2023.07.002opens in new tab/window). It appears as an Article in Press in Biological Psychiatry: Cognitive Neuroscience and Neuroimagingopens in new tab/window, published by Elsevier.

Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at [email protected]opens in new tab/window. Journalists wishing to interview the authors may contact Israel Liberzon at [email protected]opens in new tab/window.

The authors’ affiliations and disclosures of financial and conflicts of interests are available in the article.

Cameron S. Carter, MD, is Professor of Psychiatry and Psychology and Director of the Center for Neuroscience at the University of California, Davis. His disclosures of financial and conflicts of interests are available hereopens in new tab/window.

About Biological Psychiatry: Cognitive Neuroscience and Neuroimaging

Biological Psychiatry: Cognitive Neuroscience and Neuroimagingopens in new tab/window is an official journal of the Society of Biological Psychiatryopens in new tab/window, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal focuses on studies using the tools and constructs of cognitive neuroscience, including the full range of non-invasive neuroimaging and human extra- and intracranial physiological recording methodologies. It publishes both basic and clinical studies, including those that incorporate genetic data, pharmacological challenges, and computational modeling approaches. The 2022 Journal Impact FactorTM score, from Clarivate, for Biological Psychiatry: Cognitive Neuroscience and Neuroimaging is 5.9. www.sobp.org/bpcnniopens in new tab/window

Sobre a Elsevier

A Elsevier é líder global em informação avançada e suporte à tomada de decisão. Por mais de um século, ajudou a avançar a ciência e a saúde para promover o progresso humano. Apoia comunidades de pesquisa acadêmicas e corporativas, médicos, enfermeiros, futuros profissionais de saúde e educadores em 170 países, fornecendo conhecimentos críticos e soluções inovadoras que combinam conteúdo científico e médico confiável com tecnologias de IA de ponta. A Elsevier promove inclusão e sustentabilidade, incorporando esses valores em seus produtos e cultura. A Elsevier Foundationopens in new tab/window apoia pesquisas e parcerias de saúde ao redor do mundo.

A Elsevier faz parte da RELXopens in new tab/window, fornecedora global de ferramentas de análise e decisão baseadas em informação para clientes profissionais e empresariais. Para mais informações, visite www.elsevier.com e siga-nos nas redes sociais: @ElsevierConnect e @ElsevierPesquisa.